PhilipBurkeMilamMD

Dermatology • Nashville, TN

Dermatologist

Join to view full profile

Dr. Milam is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Milam's full profile

Already have an account?

Office
719 Thompson Lane
Suite 26300
Nashville, TN 37204
Phone+1 615-322-6485
Is this information wrong?

Education & Training

Ohio State University HospitalResidency, Dermatology, 2018 - 2021
Ohio State University Wexner Medical CenterFellowship, Dermatology Research, 2016 - 2018
University of Missouri-ColumbiaInternship, Internal Medicine, 2015 - 2016
East Tennessee State University James H. Quillen College of MedicineClass of 2015

Certifications & Licensure

TN State Medical License 2021 - 2025
OH State Medical License 2016 - 2022
MO State Medical License 2015 - 2016
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Outstanding Teaching Award University Missouri, Dept of Internal Medicine, 2016

Clinical Trials

Psoriasis Longitudinal Assessment and Registry Start of enrollment: 2007 Jun 21
Active, not recruiting
A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum Start of enrollment: 2014 Jan 31
Completed
Phase 2
A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus. Start of enrollment: 2014 Sep 16
Completed
Phase 2
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment Start of enrollment: 2014 Nov 03
Completed
Phase 3
The Corrona Psoriasis (PSO) Registry Start of enrollment: 2015 Apr 01
Enrolling by invitation
Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis Start of enrollment: 2016 Jun 22
Completed
Phase 3
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Start of enrollment: 2016 Oct 20
Completed
Phase 2
Study of Ixekizumab (LY2439821) in Children 6 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis Start of enrollment: 2017 Mar 28
Completed
Phase 3
An Open-Label, Proof-of-Concept Study of Ixekizumab in the Treatment of Pyoderma Gangrenosum Start of enrollment: 2017 May 04
Completed
Phase 2
The Ohio State University Dermatology Biorepository Start of enrollment: 2017 Apr 19
Recruiting
Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) Start of enrollment: 2017 Nov 17
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

2 citations
Development of a Skin-Directed Scoring System for Stevens-Johnson Syndrome and Epidermal Necrolysis: A Delphi Consensus Exercise.
Thomas, C., Waters, M., Dobry, A., Le, S., Shinkai, K., Beachkofsky, T., Davis, M., Dominguez, A., Kroshinsky, D., Markova, A., Micheletti, R., Mostaghimi, A., Pasieka...> ;JAMA Dermatology. 2023 Jul 1
1 citations
Rare missense variants in the SH3 domain ofare associated with hidradenitis suppurativa.
David J Morales-Heil, Li Cao, Cheryl Sweeney, Anna Malara, Frank Brown, Philip Milam, Milan Anadkat, Jessica Kaffenberger, Benjamin Kaffenberger, Peter Nagele, Brian K...> ;HGG Advances. 2023 Apr 13
Fibrous Proliferations in Posttransplant Kaposi Sarcoma
Kevin M Adams, Philip Milam, Alejandro A. Gru, Benjamin H. Kaffenberger> ;The Journal of Clinical and Aesthetic Dermatology. 2021 Jun 1
1 citations
Spider Telangiectases and Palmar Erythema as Harbingers of Structural Liver Changes in Three Breast Cancer Patients on Ado-trastuzumab Emtansine
Philip B. Milam, Michael Berger, Bhuvaneswari Ramaswamy, Raquel E. Reinbolt, Robert Wesolowski, Benjamin H. Kaffenberger> ;The Journal of Clinical and Aesthetic Dermatology. 2019 Jul 1
Successful treatment of inflammatory linear verrucous epidermal nevus (ILVEN) with 308‐nm excimer laser: Patient patient required
Rebecca F. Wang, Philip B. Milam, Catherine Chung, Benjamin H. Kaffenberger> ;Photodermatology, Photoimmunology & Photomedicine. 2019 May 1
Frequent skin examinations in patients with actinic keratoses: Ethical, financial, and moral implications.
Philip B. Milam, Abraham M. Korman, Jessica A. Kaffenberger> ;Journal of the American Academy of Dermatology. 2017 Nov 1
5 citations
Psoriasiform graft-versus-host disease distributed along Blaschko's lines
Philip B. Milam, Sumithra Vasu, Alejandro A. Gru, Benjamin H. Kaffenberger> ;Journal of Cutaneous Pathology. 2017 Oct 1
13 citations
Malignant intertrigo: A subset of toxic erythema of chemotherapy requiring recognition
Sabrina M. Smith, Philip B. Milam, Stephanie K. Fabbro, Alejandro A. Gru, Benjamin H. Kaffenberger> ;JAAD Case Reports. 2016 Nov 1
Join now to see all

Books/Book Chapters

Dermatologic Surgery
Chapter: Dog-ear correction
Page 230 - 241Milam PB, Carr DREditors: Kantor J, Albertini JG, Bordeaux JS, Dzubow LM, Lawrence N, Miller SJ.McGraw-Hill Education, New YorkEdition 1,2018

Hospital Affiliations

Ohio State University Wexner Medical CenterColumbus, Ohio
Vanderbilt University Medical CenterNashville, Tennessee

PhilipBurkeMilamMD

Dr. Milam is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Hospital Affiliations

Viewing the full profile is available to verified healthcare professionals only.